2026 Q2 -tulosraportti
UUTTA
5 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·35 min sittenIT CAN GO MUCH FASTER THAN PEOPLE THINK. 🧠🧬 The secret top-5 pharma partner is no longer at: "Should we test circVec?" That question has already passed. They have: → seen the technology in vitro → fully funded the project → selected candidates → taken them further in vivo And Circio is now pointing to large-pharma animal data as an important upcoming milestone in H2 2026 / H1 2027. This is where it starts to get interesting. Because the next data package doesn't just need to answer: "Does circVec work in animals?" It can also answer the much more important question for the partner: "Is this good enough for us to secure rights?" If animal data shows: → relevant expression advantage → correct tissue/cells → relevant payload → acceptable dose/safety → reproducible effect ...then the partner has suddenly come quite far down the decision tree. And this is important: They don't need to wait for human data to license a technology. A license can come when the partner believes the risk/reward is good enough. That doesn't mean a deal will come after the next readout. But it means that the distance between "next data" and "first major commercial validation" is potentially much shorter than many think. Top-5 pharma has already said yes once. First to feasibility. Then to in vivo. The next yes could be what actually gets a price tag. ♟️ We know what we own 🧱♟️🍷- ·1 t sittenTHE MOST UNDERVALUED CIRCIO MOAT IS PERHAPS NOT THE PATENTS. 🧬♟️ One important thing: Circio does not own the concept of circular RNA. Others have also worked with DNA/AAV-based circRNA before circVec. And that's not really the problem. Because in biotech, you don't need to own all the biology. You need to own the best way to make the biology work. Circio's patent track protects specific constructs and genetic elements. But the potentially larger moat is being built elsewhere: Know-how. Which elements work together? Which architecture provides the most circularization? What increases translation? What works in the heart, but not the liver? What changes with CNS? With LNP? With AAV? With a therapeutic payload instead of luciferase? And perhaps most importantly: Which combinations look fantastic on paper — but die when they meet living biology? That knowledge is not necessarily in a patent. It is built through years of: design → test → fail → understand → redesign → in vivo → repeat. That's why Gen 1 → Gen 5 is more interesting than just a larger x-number. For each generation, the Hansen team learns more about which buttons in the cell's machinery can actually be turned on simultaneously. Think of the moat like this: Patent = what others legally cannot copy. Know-how = what they don't even know they should copy. Data = the proof of which solutions actually work. Development speed = how far ahead you can get before they catch up. It's a completely different type of competitive advantage. The right question is therefore not: "Does Circio have a monopoly on circRNA?" Of course not. The question is: Can someone design around circVec and achieve the same performance, just as quickly, at the same cost? If the answer eventually becomes "not easy"… then we start talking about a real technology moat. And that moat can actually become stronger with every single experiment that is run. We know what we own 🧱♟️🍷
·1 t sittenCan we already get a repricing and see a new ATH this week ?? Circio is entering a very exciting week leading up to September 9. DNB Carnegie has pointed to CRNA as a candidate for OSEBX, and an inclusion could significantly increase interest from index funds and larger investors. A theoretical buying need of up to around 636 million kroner has been mentioned, which could lead to sharply increased volume and buying pressure in the stock. The stock closed Friday around 12.94 kr, and with continued high volume, I believe 14–15 kr is a realistic level leading up to September 9. With strong buying interest, 15–16 kr+ could also come quickly. The most interesting thing now is the combination of OSEBX, large potential fund purchases, increasing volume, and strong momentum.
Not impossible, listing leads to automatic inclusion in index funds regardless of interest.
·4 t sittenFirst, I must make a confession, and that is that I am completely out of Circio right now. That being said, I am considering putting all my eggs in one basket because I have absolute faith in the company. The reason I have gone in and out is because I have seen the opportunity for swing trading, and have actually made quite a bit of money from it. That being said, I have a feeling that now that we are moving up between 13 and 14 kr. per share, there will be a rather strong downward correction. Is this just a feeling I have because I want to inject money into the stock, or is there anyone who thinks this similarly to me? I gladly welcome constructive criticism, tips and advice, well-meaning recommendations and so on. Yes, you are also heartily welcome to write who surely have a lot on your mind and want to say ha ha what did I say, you're stupid for selling out and so on and so on. Go for it🤭😉
I believe in the stock, though. But I see what you're saying. A rally like we've had now, we also had last time before it turned down. Those. Who got a call here about lending out their shares at a price of 30%, was that when the price was around 12kr? Meaning that someone plans to get it down enough so they make money on it. Meaning more than down to 9kr. But if they manage that? No idea, but that there's a real possibility that we'll get a downturn before it turns up again? Yes, there's a real chance for that. Short is still there. Many were part of the downturn last time without selling, and it will definitely come back.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
5 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sittenIT CAN GO MUCH FASTER THAN PEOPLE THINK. 🧠🧬 The secret top-5 pharma partner is no longer at: "Should we test circVec?" That question has already passed. They have: → seen the technology in vitro → fully funded the project → selected candidates → taken them further in vivo And Circio is now pointing to large-pharma animal data as an important upcoming milestone in H2 2026 / H1 2027. This is where it starts to get interesting. Because the next data package doesn't just need to answer: "Does circVec work in animals?" It can also answer the much more important question for the partner: "Is this good enough for us to secure rights?" If animal data shows: → relevant expression advantage → correct tissue/cells → relevant payload → acceptable dose/safety → reproducible effect ...then the partner has suddenly come quite far down the decision tree. And this is important: They don't need to wait for human data to license a technology. A license can come when the partner believes the risk/reward is good enough. That doesn't mean a deal will come after the next readout. But it means that the distance between "next data" and "first major commercial validation" is potentially much shorter than many think. Top-5 pharma has already said yes once. First to feasibility. Then to in vivo. The next yes could be what actually gets a price tag. ♟️ We know what we own 🧱♟️🍷
- ·1 t sittenTHE MOST UNDERVALUED CIRCIO MOAT IS PERHAPS NOT THE PATENTS. 🧬♟️ One important thing: Circio does not own the concept of circular RNA. Others have also worked with DNA/AAV-based circRNA before circVec. And that's not really the problem. Because in biotech, you don't need to own all the biology. You need to own the best way to make the biology work. Circio's patent track protects specific constructs and genetic elements. But the potentially larger moat is being built elsewhere: Know-how. Which elements work together? Which architecture provides the most circularization? What increases translation? What works in the heart, but not the liver? What changes with CNS? With LNP? With AAV? With a therapeutic payload instead of luciferase? And perhaps most importantly: Which combinations look fantastic on paper — but die when they meet living biology? That knowledge is not necessarily in a patent. It is built through years of: design → test → fail → understand → redesign → in vivo → repeat. That's why Gen 1 → Gen 5 is more interesting than just a larger x-number. For each generation, the Hansen team learns more about which buttons in the cell's machinery can actually be turned on simultaneously. Think of the moat like this: Patent = what others legally cannot copy. Know-how = what they don't even know they should copy. Data = the proof of which solutions actually work. Development speed = how far ahead you can get before they catch up. It's a completely different type of competitive advantage. The right question is therefore not: "Does Circio have a monopoly on circRNA?" Of course not. The question is: Can someone design around circVec and achieve the same performance, just as quickly, at the same cost? If the answer eventually becomes "not easy"… then we start talking about a real technology moat. And that moat can actually become stronger with every single experiment that is run. We know what we own 🧱♟️🍷
- ·1 t sittenCan we already get a repricing and see a new ATH this week ?? Circio is entering a very exciting week leading up to September 9. DNB Carnegie has pointed to CRNA as a candidate for OSEBX, and an inclusion could significantly increase interest from index funds and larger investors. A theoretical buying need of up to around 636 million kroner has been mentioned, which could lead to sharply increased volume and buying pressure in the stock. The stock closed Friday around 12.94 kr, and with continued high volume, I believe 14–15 kr is a realistic level leading up to September 9. With strong buying interest, 15–16 kr+ could also come quickly. The most interesting thing now is the combination of OSEBX, large potential fund purchases, increasing volume, and strong momentum.Not impossible, listing leads to automatic inclusion in index funds regardless of interest.
- ·4 t sittenFirst, I must make a confession, and that is that I am completely out of Circio right now. That being said, I am considering putting all my eggs in one basket because I have absolute faith in the company. The reason I have gone in and out is because I have seen the opportunity for swing trading, and have actually made quite a bit of money from it. That being said, I have a feeling that now that we are moving up between 13 and 14 kr. per share, there will be a rather strong downward correction. Is this just a feeling I have because I want to inject money into the stock, or is there anyone who thinks this similarly to me? I gladly welcome constructive criticism, tips and advice, well-meaning recommendations and so on. Yes, you are also heartily welcome to write who surely have a lot on your mind and want to say ha ha what did I say, you're stupid for selling out and so on and so on. Go for it🤭😉I believe in the stock, though. But I see what you're saying. A rally like we've had now, we also had last time before it turned down. Those. Who got a call here about lending out their shares at a price of 30%, was that when the price was around 12kr? Meaning that someone plans to get it down enough so they make money on it. Meaning more than down to 9kr. But if they manage that? No idea, but that there's a real possibility that we'll get a downturn before it turns up again? Yes, there's a real chance for that. Short is still there. Many were part of the downturn last time without selling, and it will definitely come back.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
5 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sittenIT CAN GO MUCH FASTER THAN PEOPLE THINK. 🧠🧬 The secret top-5 pharma partner is no longer at: "Should we test circVec?" That question has already passed. They have: → seen the technology in vitro → fully funded the project → selected candidates → taken them further in vivo And Circio is now pointing to large-pharma animal data as an important upcoming milestone in H2 2026 / H1 2027. This is where it starts to get interesting. Because the next data package doesn't just need to answer: "Does circVec work in animals?" It can also answer the much more important question for the partner: "Is this good enough for us to secure rights?" If animal data shows: → relevant expression advantage → correct tissue/cells → relevant payload → acceptable dose/safety → reproducible effect ...then the partner has suddenly come quite far down the decision tree. And this is important: They don't need to wait for human data to license a technology. A license can come when the partner believes the risk/reward is good enough. That doesn't mean a deal will come after the next readout. But it means that the distance between "next data" and "first major commercial validation" is potentially much shorter than many think. Top-5 pharma has already said yes once. First to feasibility. Then to in vivo. The next yes could be what actually gets a price tag. ♟️ We know what we own 🧱♟️🍷
- ·1 t sittenTHE MOST UNDERVALUED CIRCIO MOAT IS PERHAPS NOT THE PATENTS. 🧬♟️ One important thing: Circio does not own the concept of circular RNA. Others have also worked with DNA/AAV-based circRNA before circVec. And that's not really the problem. Because in biotech, you don't need to own all the biology. You need to own the best way to make the biology work. Circio's patent track protects specific constructs and genetic elements. But the potentially larger moat is being built elsewhere: Know-how. Which elements work together? Which architecture provides the most circularization? What increases translation? What works in the heart, but not the liver? What changes with CNS? With LNP? With AAV? With a therapeutic payload instead of luciferase? And perhaps most importantly: Which combinations look fantastic on paper — but die when they meet living biology? That knowledge is not necessarily in a patent. It is built through years of: design → test → fail → understand → redesign → in vivo → repeat. That's why Gen 1 → Gen 5 is more interesting than just a larger x-number. For each generation, the Hansen team learns more about which buttons in the cell's machinery can actually be turned on simultaneously. Think of the moat like this: Patent = what others legally cannot copy. Know-how = what they don't even know they should copy. Data = the proof of which solutions actually work. Development speed = how far ahead you can get before they catch up. It's a completely different type of competitive advantage. The right question is therefore not: "Does Circio have a monopoly on circRNA?" Of course not. The question is: Can someone design around circVec and achieve the same performance, just as quickly, at the same cost? If the answer eventually becomes "not easy"… then we start talking about a real technology moat. And that moat can actually become stronger with every single experiment that is run. We know what we own 🧱♟️🍷
- ·1 t sittenCan we already get a repricing and see a new ATH this week ?? Circio is entering a very exciting week leading up to September 9. DNB Carnegie has pointed to CRNA as a candidate for OSEBX, and an inclusion could significantly increase interest from index funds and larger investors. A theoretical buying need of up to around 636 million kroner has been mentioned, which could lead to sharply increased volume and buying pressure in the stock. The stock closed Friday around 12.94 kr, and with continued high volume, I believe 14–15 kr is a realistic level leading up to September 9. With strong buying interest, 15–16 kr+ could also come quickly. The most interesting thing now is the combination of OSEBX, large potential fund purchases, increasing volume, and strong momentum.Not impossible, listing leads to automatic inclusion in index funds regardless of interest.
- ·4 t sittenFirst, I must make a confession, and that is that I am completely out of Circio right now. That being said, I am considering putting all my eggs in one basket because I have absolute faith in the company. The reason I have gone in and out is because I have seen the opportunity for swing trading, and have actually made quite a bit of money from it. That being said, I have a feeling that now that we are moving up between 13 and 14 kr. per share, there will be a rather strong downward correction. Is this just a feeling I have because I want to inject money into the stock, or is there anyone who thinks this similarly to me? I gladly welcome constructive criticism, tips and advice, well-meaning recommendations and so on. Yes, you are also heartily welcome to write who surely have a lot on your mind and want to say ha ha what did I say, you're stupid for selling out and so on and so on. Go for it🤭😉I believe in the stock, though. But I see what you're saying. A rally like we've had now, we also had last time before it turned down. Those. Who got a call here about lending out their shares at a price of 30%, was that when the price was around 12kr? Meaning that someone plans to get it down enough so they make money on it. Meaning more than down to 9kr. But if they manage that? No idea, but that there's a real possibility that we'll get a downturn before it turns up again? Yes, there's a real chance for that. Short is still there. Many were part of the downturn last time without selling, and it will definitely come back.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt